Gold you certainly opened Pandora's box on your last statement, "The problem with Constab's technology is the stability of the antibody/anti cancer agent that they are using. It has to be admnistered within two hours of formulation.
The question I would ask of Moro would be concerning the stability of his anti cancer agent. Without the ability to have a significant shelf life, just like Constab, no pharma is going to license it".
VERY INTERESTING!!!! You obviously did not or chose not to really pay attention to the patent and newest discovery. OK, Here are the bullet points again:
>This peptide opens a wide range of possibilities for delivering killing agents to cancer cells
>The synthetic peptide will allow BioCurex to replace the antibodies in the RECAF test
>Peptides are produced with an automated peptide synthesizer
>Peptide is synthesized chemically by special computer software, cost reduction is significant, more stable, resulting in longer shelf life
>To modify a peptide, all that is required is to use a different amino acid sequence on the computer, opens many possibilities for BioCurex
